Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children
暂无分享,去创建一个
F. Favata | G. di Perri | A. de Nicolò | A. D’Avolio | J. Cusato | S. Allegra | G. Fatiguso | S. De Francia | E. Pirro | C. Carcieri | A. D. De Nicolò | Giovanna Fatiguso
[1] Voriconazole , 2019, Reactions Weekly.
[2] Hongwei Zhao,et al. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes , 2017, Xenobiotica; the fate of foreign compounds in biological systems.
[3] L. Pagano,et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.
[4] Krista L. Niece,et al. In Vitro Study of the Variable Effects of Proton Pump Inhibitors on Voriconazole , 2015, Antimicrobial Agents and Chemotherapy.
[5] D. Denning,et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. , 2015, The Lancet. Infectious diseases.
[6] J. Xing,et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. , 2014, International journal of antimicrobial agents.
[7] A. McLachlan,et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.
[8] J. Xing,et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. , 2014, The Journal of antimicrobial chemotherapy.
[9] M. Hoenigl,et al. Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies , 2013, Antimicrobial Agents and Chemotherapy.
[10] F. D. De Rosa,et al. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. , 2012, The Journal of antimicrobial chemotherapy.
[11] T. Egberts,et al. Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients , 2012, Antimicrobial Agents and Chemotherapy.
[12] P. G. Choe,et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] T. Buclin,et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] A. McLachlan,et al. Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.
[15] M. Karlsson,et al. Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults , 2012, Antimicrobial Agents and Chemotherapy.
[16] D. Colantonio,et al. Therapeutic Drug Monitoring of Voriconazole in Children , 2012, Therapeutic drug monitoring.
[17] C. Elie,et al. Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency , 2011, Therapeutic drug monitoring.
[18] P. Troke,et al. Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.
[19] B. Damle,et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). , 2010, Journal of pharmaceutical sciences.
[20] F. D. De Rosa,et al. Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma , 2010, Antimicrobial Agents and Chemotherapy.
[21] Y. Fujimoto,et al. Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies , 2008, European Journal of Clinical Microbiology and Infectious Diseases.
[22] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] L. Gordon,et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.
[24] N. Wood,et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.
[25] N. Ampel,et al. American Thoracic Society Documents an Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients Contents Introduction Methods Antifungal Agents: General Considerations Polyenes Triazoles Echinocandins Treatment of Fungal Infections Hi , 2022 .
[26] G. Thompson,et al. Update on the optimal use of voriconazole for invasive fungal infections , 2011 .
[27] R. Jelliffe,et al. Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.